reveal study: long-term analysis of ruxolitinib in patients with polycythemia vera after hydroxyurea
Published 1 year ago • 1K plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
2:14
long-term 5-year data continues to show response to ruxolitinib in polycythemia vera
-
3:07
the current treatment algorithm for polycythemia vera
-
5:08
polycythemia vera - causes, symptoms, diagnosis, treatment, pathology
-
2:38
ongoing data from the phase 3 response trial of ruxolitinib for polycythemia vera
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
2:55
pv-aim: using machine learning to predict resistance to hydroxyurea therapy in patients with pv
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
1:35
pv-pinpoint: a study investigating the diagnosis and management of polycythemia vera in the uk
-
2:12
refine: phase ii study of navitoclax ruxolitinib in jak inhibitor-naive patients with mf
-
3:09
real-world data analysis of ruxolitinib in myelofibrosis
-
3:06
results from the majic-pv trial: ruxolitinib vs bat for hydroxyurea resistant/intolerant pv
-
6:31
the current treatment landscape for polycythemia vera
-
1:46
results for the follow-up of the response study
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
2:57
preliminary data from the manifest study: pelabresib in combination with ruxolitinib in mf
-
1:06
long-term outcomes of the ocean study: melflufen is superior to pomalidomide in r/r myeloma
-
2:46
an update on emerging therapies for the treatment of polycythemia vera
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis